Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $17.7252W HIGH $44.28
Volume
169.64 K
Value Traded
13.06 M
Short % Float
6.74%
Days to Cover
6.0
+11.31%Week
+3.63%1 Month
+31.5%3 Month
+48.41%6 Month
-65.98%5 Year
+0.75%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.12 B
EPS (TTM)
-0.64
P/E Ratio
-
Ent. Value
869.19 M
Total Shares
30.54 M
Float Shares
29.94 M
Insiders
2.00%
Institutions
91.38%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CSTL Catalyst Timeline
Dated clinical, regulatory and corporate events for Castle Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Castle Biosciences, Inc.
282Total events
3Upcoming
23Tier-1 (high impact)
2019 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationTissueCypherPresentation
Poster P5192: Real-world multi-center cohort study of TissueCypher impact on BE management
Barrett's Esophagussource ↗
●R&D DayTissueCypherPresentation
TissueCypher Product Theater at ACG 2026 featuring patient ambassador Johnny Walker
Barrett's Esophagussource ↗
●Poster PresentationTissueCypherPresentation
Poster P3056: TissueCypher detected missed prevalent dysplasia in presumed low-risk NDBE patient
Barrett's Esophagussource ↗
▲PublicationTissueCypherPresentation
Study published in Foregut showing TissueCypher changed management in 90% of NDBE patients
non-dysplastic Barrett's esophagus (NDBE)source ↗
▲Poster PresentationTissueCypherPresentation
TissueCypher NDBE management study presented at American College of Surgeons Clinical Congress 2026
non-dysplastic Barrett's esophagus (NDBE)source ↗
▲Manufacturing MilestoneCMC / Inspection
Opening of new 55,000-square-foot laboratory and office facility in Scottsdale, Arizona
▲Other Regulator MilestoneAdvanceAD-TxEx-US Regulatory
AdvanceAD-Tx received assay approval from New York State Department of Health
Atopic Dermatitissource ↗
▲PublicationDecisionDx-MelanomaFiledPresentation
Publication of prospective multicenter study showing i31-SLNB outperforms MIA nomogram
Cutaneous Melanomasource ↗
▲Enrollment MilestoneTissueCypherTrial
TissueCypher test surpasses 100,000 orders
Barrett's esophagussource ↗
▲First Patient DosedTrial
First patient enrolled in DETECT-AD study assessing flare prediction in atopic dermatitis
Atopic Dermatitissource ↗
▲Oral PresentationAdvanceAD-TxPresentation
Data presented at Revolutionizing Atopic Dermatitis meeting showing AdvanceAD-Tx guided treatment concordance
Atopic Dermatitissource ↗
▲Breakthrough Therapy DesignationAdvanceAD-TxDesignation
AdvanceAD-Tx receives 2026 MedTech Breakthrough Award for Genomics Innovation
moderate-to-severe atopic dermatitissource ↗
▲Quarterly UpdateCorporate
AdvanceAD-Tx won Genomics Innovation Award in MedTech Breakthrough Awards
▲Oral PresentationTissueCypherPresentation
TissueCypher improves risk stratification and informs management decisions at DDW
Barrett's esophagussource ↗
▲Oral PresentationDecisionDx-MelanomaFiledPresentation
DecisionDx-Melanoma provides independent prognostic info beyond AJCC staging at EADO and ACMS
cutaneous melanomasource ↗
◆Poster PresentationDecisionDx-MelanomaFiledPresentation
Poster presentation at AAD 2026 Annual Meeting
cutaneous melanomasource ↗
▲Oral PresentationDecisionDx-MelanomaFiledPresentation
DecisionDx-Melanoma refines mortality risk within AJCC stages at AAD 2026
cutaneous melanomasource ↗
◆Oral PresentationDecisionDx-MelanomaFiledPresentation
Data presented at SSO 2026 Annual Meeting
cutaneous melanomasource ↗
▲Full ResultsDecisionDx-MelanomaFiledClinical Data
Prospective multicenter study results for i31-SLNB published in Future Oncology
cutaneous melanomasource ↗
◆Poster PresentationDecisionDx-MelanomaFiledPresentation
ePoster EP49: i31-SLNB identifies T1b-T2a melanoma patients who can safely avoid SLNB
cutaneous melanomasource ↗
◆Quarterly UpdateCorporate
Q4 and full-year 2025 financial results release and conference call
▲PublicationAdvanceAD-TxPresentation
AdvanceAD-Tx validation study published in JAAD
moderate-to-severe atopic dermatitissource ↗
●Quarterly UpdateCorporate
Year-end 2025 cash, cash equivalents & marketable securities expected ~$300 million
▲PublicationPresentation
Publication of COOG2 study in Nature Communications comparing DecisionDx-UM + PRAME vs NGS mutation analysis
uveal melanomasource ↗
●PublicationDecisionDx-UMPresentation
Publication of COOG study in Nature Communications
uveal melanomasource ↗
▲PublicationTissueCypherPresentation
Publication of SRMA in Journal of Clinical Gastroenterology
Barrett's esophagussource ↗
▲PublicationDecisionDx-MelanomaFiledPresentation
Publication of expert consensus paper endorsing DecisionDx-Melanoma
cutaneous melanomasource ↗
◆Oral PresentationPresentation
Castle Biosciences to present at Piper Sandler 37th Annual Healthcare Conference
◆Quarterly UpdateCorporate
One-on-one investor meetings at Jefferies Global Healthcare Conference
●Oral PresentationDecisionDx-MelanomaFiledPresentation
Two oral presentations at 2nd European Congress on Dermato-Oncology
cutaneous melanomasource ↗
▲Product LaunchAdvanceAD-TxPost-Market
Limited access launch of AdvanceAD-Tx
moderate-to-severe atopic dermatitissource ↗
▲PublicationAdvanceAD-TxPresentation
Publication of development and validation study in JAAD
moderate-to-severe atopic dermatitissource ↗
▲Product LaunchAdvanceAD-TxPost-Market
Launch of AdvanceAD-Tx test
moderate-to-severe atopic dermatitissource ↗
▲Product LaunchAdvanceAD-TxPost-Market
Measured limited access launch begins
moderate-to-severe atopic dermatitissource ↗
◆Poster PresentationTissueCypherPresentation
Three posters at ACG 2025 Annual Scientific Meeting, including one Presidential Poster Award
Barrett's esophagussource ↗
◆Poster PresentationDecisionDx-MelanomaFiledPresentation
Poster presentation on 31-GEP test stratifying melanoma-specific survival across histological subtypes
cutaneous melanomasource ↗
◆Poster PresentationPresentation
Poster presentation on 487-GEP test guiding systemic therapy selection for atopic dermatitis: results from prospective, multi-center trial
atopic dermatitissource ↗
◆Quarterly UpdateCorporate
One-on-one investor meetings at 9th Annual Lake Street Best Ideas Growth (BIG9) Conference
Past FDA Catalysts and PDUFA Decisions
How CSTL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
7
Drugs Scored
rNPV / MCap
Top Drug
Top 69%
Micro Cap(rank 454 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every CSTL program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Juvenal Tobin WOfficer (Chief Commercial Officer) | Sell | -3,288 45,431 held | $33.08 | 10/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CSTL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 0.6 % (-14.3 %) | 66.26 M | 2.78 M | 0.73% ( 20.00 K) |
CSTL Institutional Ownership Trends
CSTL Short Interest
Shares sold short, counted twice a month.
6.74%
Short % of Float
of tradable shares sold short
2.0M
Shares Sold Short
+0.8% vs prior count
6.0 High
Days to Cover
trading days of normal volume to buy every short share back
337.1K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CSTL ranks across every disease it competes in
Competitive Position is a premium feature
See how CSTL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCSTL News
CSTL▲ +6.3%on this news
Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences, Inc. (CSTL) announced its participation in the Stephens Annual Investment Conference on Nov. 18, 2026. The company will present an overview and is also available for one-on-one meetings at the Jefferies Global Healthcare Conference from Nov. 16-19, 2026. Their focus is on innovative tests that guide patient care.
Read more →CSTLCastle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026
Castle Biosciences, Inc. announced it will release its third quarter financial results on November 5, 2026, after market close. A webcast will follow at 4:30 p.m. ET for management to discuss the results and answer questions. The company emphasizes its commitment to improving health through innovative diagnostic tests.
Read more →CSTLACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
Castle Biosciences announced new data on its TissueCypher Barrett's Esophagus test, presented at the ACG 2026 meeting. The studies demonstrate how TissueCypher can enhance risk assessment beyond traditional biopsy findings, leading to more tailored patient management. The test's ability to predict progression to high-grade dysplasia or esophageal adenocarcinoma is emphasized, supporting timely interventions.
Read more →CSTLLate-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
Castle Biosciences presented new data on DecisionDx-Melanoma at the EADV Congress 2026. The study involved 2,799 patients and demonstrated that low-risk patients had a sentinel lymph node positivity rate below 5%. Additionally, those who avoided sentinel lymph node biopsy achieved a five-year recurrence-free survival rate of 99.6%, indicating effective risk stratification.
Read more →CSTLNew Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
Castle Biosciences announced a study showing that its TissueCypher Barrett's Esophagus Test significantly influenced management decisions for 90% of patients with non-dysplastic Barrett's esophagus. The test allowed clinicians to tailor treatment based on individual risk levels, enhancing patient care. Findings were presented at the American College of Surgeons Clinical Congress 2026.
Read more →CSTLNew Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
A new study published by Castle Biosciences emphasizes the need for molecular guidance in treating atopic dermatitis. It reveals that over half of patients using targeted systemic therapies altered their treatment due to ineffectiveness. The study found a strong interest among patients for molecular testing to enhance treatment selection, supporting the utility of Castle's AdvanceAD-Tx test.
Read more →CSTLCastle Biosciences to Open New Laboratory Facility in Scottsdale
Castle Biosciences has announced the opening of a new 55,000-square-foot laboratory facility in Scottsdale, Arizona, aimed at supporting its growing operations. The facility will enhance the company's capacity and infrastructure, allowing for improved patient care. A grand opening event is scheduled for October 6, 2026, with local officials expected to attend.
Read more →CSTL▲ +6.2%on this news
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
Castle Biosciences announced a study showing that its TissueCypher test significantly improves management for patients with Barrett's esophagus. The study found that using TissueCypher could nearly double the appropriate escalation of care for patients at risk of progression to cancer. Additionally, it reduces unnecessary procedures for patients unlikely to progress.
Read more →CSTLJAAD Publication Shows Improved Performance of DecisionDx®-SCC
Castle Biosciences announced a study published in JAAD validating the DecisionDx-SCC test, which integrates genetic and clinicopathologic factors for high-risk cutaneous squamous cell carcinoma (SCC). The enhanced algorithm significantly improves risk stratification, demonstrating a 97.3% negative predictive value for low-risk patients and identifying those who would benefit from adjuvant radiation therapy. This advancement aims to support more informed treatment decisions.
Read more →CSTLCastle Biosciences Approved for Dual Listing on Nasdaq Texas
Castle Biosciences has received approval for a dual listing on Nasdaq Texas while maintaining its primary listing on Nasdaq Global Market. This move is expected to enhance the company's visibility among investors and reflects its commitment to Texas as a hub for life sciences innovation. The dual listing will not impact the company's business operations or capital structure.
Read more →CSTLCastle Biosciences Reports Second Quarter 2026 Results
Castle Biosciences reported a strong second quarter for 2026, achieving revenues of $103.5 million, a 32% increase from the previous year. The company raised its full-year revenue guidance to between $365-375 million, driven by growth in core test reports. Despite a net loss of $2.1 million, positive Adjusted EBITDA is expected for the remainder of the year, indicating strong operational performance.
Read more →CSTLCastle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
Castle Biosciences, Inc. will present an overview at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The presentation will be available via a live audio webcast on the company's website, with a replay accessible afterward. The company specializes in innovative diagnostic tests aimed at enhancing patient care.
Read more →CSTLCastle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
Castle Biosciences has received approval from the New York State Department of Health for its AdvanceAD-Tx test, designed to guide systemic treatment decisions for patients with moderate-to-severe atopic dermatitis. This non-invasive test analyzes gene expression from skin samples to classify patients into molecular profiles, helping clinicians select the most effective therapies. The approval enhances patient access to this innovative diagnostic tool in New York.
Read more →CSTLCastle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
Castle Biosciences, Inc. will announce its second quarter financial results for 2026 on July 30, 2026, after market close. A webcast will follow at 4:30 p.m. Eastern time, allowing stakeholders to discuss the results. The company emphasizes its commitment to innovative diagnostics in patient care.
Read more →CSTL▲ +6.1%on this news
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
A new study reveals that Castle Biosciences' DecisionDx-Melanoma i31-SLNB test outperforms the MIA nomogram in predicting sentinel lymph node (SLN) positivity in melanoma patients. The i31-SLNB test identified low-risk patients with a 2.6% SLN positivity rate, significantly below the NCCN threshold. This advancement aids clinicians in making informed decisions regarding SLNB procedures.
Read more →CSTLCastle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
Frank Stokes, CFO of Castle Biosciences, has been honored as a 2026 CFO Awards honoree by the Houston Business Journal. He is recognized for his financial leadership and contributions to the company's success. Stokes has been with Castle since 2017 and played a key role in its IPO and strategic growth. The awards event will take place on July 30, 2026.
Read more →CSTLCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Castle Biosciences announced the grant of restricted stock units (RSUs) to 172 employees as part of its 2022 Inducement Plan. The RSUs, totaling 204,925 shares, will vest over four years, promoting employee retention. This move complies with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to its workforce.
Read more →CSTLCastle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
Castle Biosciences announced that its TissueCypher Barrett's Esophagus Test has surpassed 100,000 clinical test orders. This AI-derived test predicts the five-year risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, aiding clinicians in personalizing patient management. The milestone reflects increasing adoption and positive patient feedback.
Read more →CSTLFirst Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
SciBase has enrolled the first patient in a clinical study aimed at predicting flare-ups in atopic dermatitis. The DETECT-AD study will utilize Electrical Impedance Spectroscopy to identify early signs of flares, shifting from reactive to proactive treatment approaches. This initiative seeks to improve patient quality of life and reduce the unpredictability of flare-ups.
Read more →About Castle Biosciences, Inc.
Headquarters1500 W. PARKWOOD AVE., FRIENDSWOOD, TX, 77546
BIOPHARMAWATCH ELITE PLUS
Trade the next CSTL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime